Abstract In May 2016, the Global Polio Eradication Initiative (GPEI) coordinated the
cessation of all use of type 2 oral poliovirus vaccine (OPV2), except for emergency outbreak …

Abstract The Global Polio Eradication Initiative (GPEI) partners engaged modelers during
the past nearly 20 years to support strategy and policy discussions and decisions, and to …

Delays in achieving the global eradication of wild poliovirus transmission continue to
postpone subsequent cessation of all oral poliovirus vaccine (OPV) use. Countries must stop …

Background Despite the successes of the Global Polio Eradication Initiative, substantial
challenges remain in eradicating the poliovirus. The Sabin-strain (live-attenuated) virus in …

Introduction Detection of poliovirus transmission and ongoing oral poliovirus vaccine (OPV)
use continue to delay poliomyelitis eradication. In 2016, the Global Polio Eradication …

Background Wild type 2 poliovirus was last observed in 1999. The Sabin-strain oral polio
vaccine type 2 (OPV2) was critical to eradication, but it is known to revert to a neurovirulent …

Due to the very low, but nonzero, paralysis risks associated with the use of oral poliovirus
vaccine (OPV), eradicating poliomyelitis requires ending all OPV use globally. The Global …

Background Following successful eradication of wild polioviruses and planned globally-
coordinated cessation of oral poliovirus vaccine (OPV), national and global health leaders …

To achieve complete polio eradication, the live oral poliovirus vaccine (OPV) currently used
must be phased out after the end of wild poliovirus transmission. However, poorly …

Appropriate response to polio outbreaks represents an important prerequisite for achieving
and maintaining global polio eradication. We use an existing dynamic disease transmission …